Hosted on MSN

Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals

In the first nine months of 2025, Tempus AI Inc. TEM achieved several key regulatory milestones that strengthened its position in AI-driven diagnostics. In September 2025, the company received FDA 510 ...
Hosted on MSN

Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD

RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and ...
Business Wire

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) ...
Crain's Chicago Business

Lefkofsky sees more runway ahead for now-profitable Tempus

Chicago artificial intelligence giant Tempus AI is showing it's operating in the black after 10 years and growing.
GEN - Genetic Engineering and Biotechnology News

The Throughput Paradox: Why Next-Generation Sequencing Bottlenecks Persist Beyond the Sequencer

The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue to witness sequencer throughput expansion with systems like the Illumina ...